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Evaluating Mitochondrial Uncoupling Potentials of A7E and DNP in Saccharomyces
cerevisiae: Implications for Human Obesity.
by

Roger Alan Vaughan
B.S., Nutrition and Dietetics, University of New Mexico, 2008
M.S., Nutrition, University of New Mexico, 2011

ABSTRACT
Obesity is one of the most prevalent maladies in the United States and is a major cause of
preventable death. Weight loss supplements frequently claim uncoupling as a mechanism
of action. Uncoupling agents could be used for weight loss because they disrupt
mitochondrial metabolism thereby reducing adenosine triphosphate (ATP) yield.
Consequently, metabolic efficiency diminishes increasing basal metabolic rate. 2,4Dinitrophenol (DNP) successfully uncouples but was banned in 1938 because of a narrow
window between efficacy and toxicity. PURPOSE: To measure the ability of a blend that
reportedly contains 17-dihydroxy-delta-5-etiocholane-7-one and pmethylcarbonylethylphenol and other substances (A7E), a purported uncoupling agent, to
interfere with oxidative phosphorylation in Saccharomyces cerevisiae as evidenced by
lower ATP production. METHODS: Timed culture studies of S. cerevisiae were
performed using two separate agents, A7E (a purported uncoupling agent) and DNP (a
known uncoupling agent) at three doses (DNP: Low, Moderate, High; A7E: Low,
Moderate, High ), and an ethanol-treated control to detect interference with mitochondrial
vii

coupling. Microbial staining was used to ascertain cell viability and any changes in cell
densities. ATP production was estimated by measuring luminosity generated in culture
supernatants using the ATP Bioluminescence Kit (Sigma St. Louis, MO.). RESULTS:
Luminosity measurements estimating ATP production revealed statistically lower ATP in
agent-treated supernatants than in control supernatants (p < 0.001) except for low dose
A7E versus control (p > .05), suggesting that both A7E and DNP acted by a mechanism
of uncoupling. Luminosity values were measured in relative luminosity units (RLU).
Treatments with A7E at Low, Moderate, and High doses generated group mean
luminosity values of 24,596, 16,038, and 6,969, respectively. Treatments with DNP at
Low, Moderate, and High doses generated group mean luminosity values of 17,191,
11,901, 767 RLU respectively. The control group mean was 31,645 RLU. Culture
studies had no statistical difference (p > 0.0167 adjusted) in total and viable cell densities
between the control and A7E and DNP treatments. CONCLUSION: A7E is effective at
reducing ATP levels in this assay, as is known uncoupling agent DNP, supporting the
hypothesis that A7E may also uncouple oxidative phosphorylation. Because A7E requires
a higher dosage than DNP to equivalently disrupt mitochondrial metabolism, it may have
a wider range of therapeutic doses. This suggests that A7E should be studied further for
safety and efficacy with respect to metabolic efficiency and weight loss.
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Chapter 1 Introduction
Obesity has rapidly become one of mankind’s most prevalent preventable maladies.
According to the U.S. Department of Health and Human Services, roughly 60% of adults
in the United States are overweight, and approximately 30% of them are considered
obese [1]. In 1994, when the CDC had recorded values for all 50 states, 35 of the states
had obesity prevalence between 10 and 14% and only 15 states had prevalence greater
than 14% but less than 20%. In 2004 the CDC estimated that over 34% (approximately
72 million Americans) of adults age 20 and over were obese [2]. In 2007, the CDC
reported that only one state in America (Colorado) had prevalence of obesity lower than
20% and, that 6 states (Alabama, Mississippi, Oklahoma, South Carolina, Tennessee, and
West Virginia) had a population with more than 30% obesity prevalence [2]. As a result
of its prevalence, obesity is one of the leading causes of preventable death. The obesity
epidemic in America increases healthcare costs by an estimated $147 billion annually [3].
A combination of factors has contributed to the current co-morbidities that
Americans face. Many healthcare professionals agree that a combination of food overabundance, sedentary lifestyle, and genetic predisposition has resulted in the obesity
pandemic that exists today. Obesity is generally characterized by an excessively high fat
mass, usually accompanied by a high ratio of body weight to height. Most health care
professionals utilize a systematic classification system known as the body mass index
(BMI). The BMI measurements are calculated by dividing the subject’s weight (kg) by
the subject’s height (m2). BMI classifications include:
 Obese - Values > 30
1

 Overweight - Values between 25 and 29.9
 Ideal weight - Values between 18.5 and 24.9
 Underweight - Values < 18.5
Obesity has many contributing factors including increased food availability, increased
food intake, sedentary lifestyles, and potential genetic predisposition. It is hypothesized
that many Americans have what is known as a “thrifty gene”. In actuality, the thrifty gene
is not one gene, but a combination of genetic and environmental factors that allows
individuals in this set of circumstances to be more efficient in their use of energy,
resulting in reduced energy need. During times of famine it was advantageous to be
efficient at storing energy in adipose tissue; however, when there is more than enough to
eat and people can survive with limited movement, the thrifty gene promotes fat storage
to a detrimental degree [4].
It has also been established that people with low socioeconomic status have a
greater probability of becoming obese in developed nations with plentiful food. Minority
groups have greater prevalence of obesity than non minority groups and low
socioeconomic status may play a more profound role in these groups [5].
Obesity is an individualized disease, and it is beneficial to have many diverse
treatment approaches. There are a variety of current weight management approaches that
are used. Individuals may use any number of treatments including medically or nonmedically supervised calorie restriction (dieting), meal replacement pack supplements,
group therapy sessions (e.g., Overeaters Anonymous), low-calorie prepackaged foods
(e.g., Jenny Craig), bariatric surgery, liposuction, over-the-counter (OTC) supplements,
and several other options. In addition, physicians may prescribe pharmaceutical
2

interventions (e.g. appetite suppressants or macronutrient absorption inhibitors). Current
pharmaceutical agents include phentermine, sibutramine, orlistat, and diethylproprion [6].
These agents, although somewhat effective at appetite reduction or lipid mal-absorption,
are not effective for everyone and have unwanted side effects. Moreover, many of these
drug interventions have not been approved for use longer than 12 weeks. Uncoupling
agents like dinitrophenol (DNP) [6-9] have shown positive results in animal models as an
anti-obesity agent but can have extreme toxic effects [6, 10]. It is clear that no single
treatment or combination of treatments is correct for every person. Therefore, it is
essential to explore and pursue every option until obesity is constrained.

Purpose
This work specifically seeks to determine if the active ingredients in the blend
(A7E) that comprises the over-the-counter supplement HOTROXTM specifically
uncouple mitochondrial membranes interfering with oxidative phosphorylation. The
blend A7E purportedly contains 17-dihydroxy-delta-5-etiocholane-7-one and
p-methylcarbonylethylphenol (believed to be the active uncoupling agent/s) as well as
many other ingredients.

Hypothesis
I hypothesized that the A7E uncoupling agent alters mitochondrial metabolism in
Saccharomyces cerevisiae by interfering with oxidative phosphorylation by means of
proton translocation and that A7E is less effective at uncoupling mitochondria than DNP
(positive control). In order to address this hypothesis, I investigated the effects of both
A7E and DNP on the process of oxidative ATP production in the eukaryote S. cerevisiae
3

by comparing A7E and DNP at varying doses on the growth and ATP production in S.
cerevisiae with a control treated with ethanol alone.

Testable Hypotheses
Following treatment of S. cerevisiae at defined doses and incubation:
1. Null- There is no difference in cell density between untreated yeast cells and yeast
cells treated with either A7E and DNP
2. Null- There is no difference in ATP production between controls and those treated
with varied amounts of DNP
3. Null- There is no difference in ATP production between controls and those treated
with varied amounts of A7E
4. Null- There is no difference in ATP production between those treated with DNP
and those treated with A7E
See discussion for individual statistically analyzed testable hypotheses

Definitions
Adenosine Triphosphate (ATP) - a phosphorylated nucleotide C10H16N5O13P3
composed of adenosine and three phosphate groups that supplies energy for many
biochemical cellular processes by undergoing enzymatic hydrolysis especially to
adenosine diphosphate (ADP)
β-oxidation- catabolism of fatty acids in which two-carbon chains are removed from the
carboxyl end of the fatty acid. Conversion of fatty acids to acetyl Co-A
Basal Metabolic Rate- oxygen cost of energy expenditure measured under basal
(resting) conditions
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Calorie Deficit- Energy intake less than energy expenditure resulting in a state of
catabolism
Cellular Respiration- any of various energy-yielding oxidative reactions in living matter
that typically involve utilization of oxygen and production of carbon dioxide and water as
end products
Cytochrome- any of several intracellular hemoprotein respiratory pigments that are
enzymes functioning in electron transport as carriers of electrons
Glycolysis- the enzymatic breakdown of a monosaccharide resulting in the metabolic end
product pyruvate. Conversion of glucose, fructose or galactose to pyruvate
Mitochondria- any of various round or long cellular organelles of most eukaryotes that
are found outside the nucleus which produce energy for the cell through cellular
respiration and oxidative phosphorylation
Mitochondrial intermembrane space- Space between the inner and outer mitochondrial
membranes where proton concentration gradients accumulate
NADH- the reduced form of NAD, a vitamin co-factor that acts as an electron carrier in
many biochemical reactions, including many of those required for energy yield
Oxidative Phosphorylation- the synthesis of ATP by phosphorylation of ADP for which
energy is obtained by electron transport and which takes place in the mitochondria during
aerobic respiration
Proton Translocation- Process of protons reentering the mitochondrial matrix from the
mitochondrial intermembrane space independent of ATP synthase (Complex V)
Redox Reaction- a chemical reaction in which one or more electrons are transferred
from one atom or molecule to another
5

Socioeconomic Status- the position of an individual on a social-economic scale that
measures such factors as education, income, type of occupation, place of residence, and,
in some populations, heritage and religion
Uncoupling Agents- substances that allow protons that have accumulated in the intermitochondrial space to translocate back into the mitochondrial matrix
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Chapter 2 Background
Mitochondrial cell uncoupling agents have been used to assist in weight loss as fat
burners [11, 12]. The addition of such compounds to a consistent diet and exercise
program is suspected to notably reduce obesity. The potential uncoupling agent A7E is
available commercially in a product called HOTROXTM produced by Biotest. Biotest
states that A7E up-regulates fat burning, mobilizes fat stores for energy requirements, and
decreases fat storage during occasional overeating. It is also stated that HOTROXTM may
induce uncoupling [13]. A7E may be functionally similar to the known uncoupling agent
DNP. There are no published studies that reveal a relationship between A7E and an
interference with mitochondrial respiration, and uncoupling. My investigation will
therefore be the first experiment to address these issues.

Function and Biochemistry
Tri Carboxylic Acid Cycle
The body has many metabolic pathways that transform macronutrients into energy
via metabolic intermediates and vitamin cofactors, including glycolysis and β-oxidation.
The end products of these reactions eventually enter the tri-carboxylic acid cycle (Kreb’s
Cycle). The cycle is initiated with a 6-carbon citrate molecule which undergoes several
reactions releasing CO2. This cleavage allows the molecule to undergo redox reactions
involving electron transfer ultimately yielding reduced co-enzyme products, NADH+H+
and FADH2 [14]. These electron carriers continue oxidative metabolism by entering the
electron transport chain (ETC).
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Electron Transport Chain
If oxygen is present, NADH+H+ and FADH2 will enter the ETC. The electron
transport chain is subdivided into five complexes. In Complex I, NADH+H+ donates
electrons directly to electron donor flavin mononucleotide (FMN) which donates through
an iron/sulfur base which reduces ubiquinol to ubiquinone. During this process, four
protons are released into the intermembrane space and two are consumed in the redox
reaction. This process takes place independent of Complex II. In Complex II, succinate
dehydrogenase oxidizes succinate forming fumerate, a process that reduces FAD to
FADH2 which ultimately reduces ubiquinol to ubiquinone. Electrons are transferred to
Complexes I and II (Figure 1) in the form of two protons.

Figure 1. Complexes I and II of ETC

In Complex III, Cytochrome C is reduced and ubiquinol becomes oxidized
(Figure 2). Cytochromes are iron-based electron transferring proteins that are unable to
accept protons. This is significant because there is a sequential transfer of four protons
that are transported into the intermembrane space.
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Figure 2. Complex III of ETC

Cytochrome C is then transferred to a large integral protein with many membrane
spanning regions forming Complex IV or Cytochrome C Oxidase (Figure 3). Cytochrome
C is oxidized in Complex IV and the electrons are propelled back into the matrix where
they combine with 2 protons and oxygen forming metabolic water [15].

Figure 3. Complex IV (Cytochrome C Oxidase)

During Complexes I, III, and IV, protons are pumped against the concentration
gradient though the inner mitochondrial membrane into the inter-membrane space. This
yields an inequality between internal and external electrical charges and proton
concentration. Protein channels facilitate diffusion of protons across the inter-membrane
and back into the matrix. These channels are paired protein aggregates existing in two
sectors, F1 and F0. F1 is the catalytic sector located in the matrix comprised of three alpha
9

and three beta subunits. The beta subunits are the active site for ADP phosphorylation.
The force of proton ions flowing back into the matrix drives the attachment of adenosine
diphosphate (ADP) and inorganic phosphate group (Pi) forming ATP, a reaction
catalyzed by ATP synthase. This process is oxidative phosphorylation which is initiated
by transport protein aggregates working sequentially to form Complex V(Figure 4) [15].

Figure 4. Complex V of ETC ATP Synthase (F-Type ATPase)

The initial concentration gradient is important because if ion disequilibrium is not
great enough then there will not be sufficient energy to produce ATP. Thus, electron
transport and oxidative phosphorylation are said to be coupled. Electron transport and
oxidative phosphorylation are illustrated in Figure 5.
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Figure 5. Electron Transport Pathway

Mitochondrial Uncoupling Agent Function
Uncoupling agents work against ATP production by reducing the proton
concentration gradient using proton translocation by allowing protons to seep across the
mitochondrion membrane independent of Complex V (ATP synthase), an essential step in
ATP synthesis (Figure 4). This action inhibits ATP synthesis by channeling the proton
concentration gradient through the inner mitochondrial membrane independent of ATP
synthase [15]. The electronegative effect of the oxygen in the intracellular matrix drives
the redox reactions that create the proton gradient responsible for ATP synthesis.
Whenever protons are allowed to seep back into the matrix, oxygen accepts protons to
form metabolic water that satisfies the electronegative driving force and inhibits
oxidative phosphorylation (Figure 6).

11

Figure 6. Uncoupled Mitochondrial Electron Transport

Figure 7 illustrates the chemical similarities of known uncoupling agent 2,4-dinitrophenol
and a proposed structure of one of the purported ingredients in the A7E blend, pmethylcarbonylethylphenol.

DNP

p-MCEP

O

Figure 7. Chemical structure of DNP and A7E. A7E purportedly contains p-MCEP and Figure 7 is a
proposed structure.
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Once sufficient uncoupling agents are present in the mitochondrial, oxidative
metabolism normally resulting in ATP production will become less efficient resulting in
additional exogenous fuel demands to produce a given amount of ATP. This increased
oxidative metabolism without ATP production dissipates significant energy as heat. In an
attempt to compensate for the increased fuel utilization to produce a given amount of
ATP, cells will have an ongoing requirement for increased fuel creating a whole body
energy deficit if food intake does not increase compared to the heightened cellular fuel
requirement for a given amount of ATP production. Humans lose weight as a result of
calorie deficit; therefore, the use of uncoupling agents with a consistent diet and exercise
program will theoretically yield greater weight loss than diet and exercise alone. Loss of
fat has been demonstrated as a result of diminished ATP synthesis [11].

Brown Adipose Tissue
Brown adipose tissue (BAT) is a topic of recent interest due to the presence of
uncoupling protein 1 (UCP1), an uncoupling protein imbedded in the membrane of
mitochondria specific to BAT [16-18]. BAT plays a role in energy homeostasis by using
UCP1 for thermogenesis [16-18]. Until recently it was presumed that BAT was only
present and functional in certain mammals and human infants [16, 18]. Recently it was
identified that human adults do possess functional BAT in measurable quantities [16].
BAT appears to be more prevalent in women than men and appears to be inversely
related to BMI [16]. Similarly, a comparative study of BAT distribution in cold-exposed
adult men found that obesity was associated with reduced BAT activity [18]. Ectopic
portions of BAT have been isolated in white adipose tissue (WAT) in a process known as
recruitment, which might increase thermogenesis and subsequently play a role in energy
13

balance [17]. It has been documented that chemical agents such as fucoxanthin from sea
weed and a novel plant extract from Cirsium oligophyllum can increase expression of
BAT in rat studies [19, 20]. It is postulated that if adult humans have active BAT present,
then stimulating the uncoupling provided by UCP1 could play a vital role in the treatment
and prevention of obesity.

DNP
DNP is a confirmed uncoupling agent [7-9, 21] that has been used for weight loss
[11, 12]. Various research suggests that DNP and related uncoupling agents up-regulate
energy consumption via heat dissipation by mitochondria in cells. It has been postulated
that, through the increase of mitochondrial proton leak, a decrease in the efficiency of
oxidative phosphorylation could result, combating obesity by enabling fatty acids to be
oxidized with a decrease in ATP yield [6, 21]. If more energy is dissipated as heat as a
result of less efficient ATP production [22] during cellular respiration, then a larger
energy-deficit could be attained thus resulting in greater weight loss [6]. DNP was
originally researched at Stanford University using animal models to assess the effect of
the nitrophenols on basal metabolic rate (BMR). The studies concluded DNP could
increase BMR by 40% [6] and the drug was widely introduced to the public in 1933
despite warnings that the drug should only be used experimentally [6]. This rise in BMR
is proportional to the dosage of uncoupling agent administered. DNP was removed from
sale in 1938 as a result of its severe side effects [10], which include severe fever / brain
damage, dermatitis, agranulocytosis, hepatotoxicity, visual impairment, and death.
Because DNP has high lethality resulting from its strong uncoupling, it is not an
appropriate agent for therapeutic weight loss, however an uncoupling agent that is less
14

efficient at performing proton translocation could be an effective addition to obesity
management [21, 23]. Conceivably, a weaker uncoupling agent would create a less
wasteful oxidative mitochondrial metabolism, while simultaneously widening the
therapeutic dose of the drug, reducing toxicity. Uncoupling agents have also been shown
to dynamically decrease fatty acid synthesis while increasing fatty acid oxidation [24].

A7E
To date, there is no published literature examining A7E’s roles as an uncoupling
agent. However, A7E might elicit a therapeutic mitochondrial interference with a dose
response that could be used effectively by humans for weight loss. This work will
demonstrate what effect, if any, A7E has on oxidative phosphorylation.

Test Organism
Saccharomyces cerevisae is the model organism for my study because it has been
used as the test organism in previous examinations of DNP [25, 26] and other uncoupling
agents [25, 26]. Uncoupling agents have been shown to reduce production of ATP in S.
cerevisiae [27]. The eukaryote S. cerevisiae is a model organism for estimating human
ATP production because the mitochondria found in S. cerevisiae have identical
cytochrome sequences to mitochondria present in human cells and share identical
functions, which can be inhibited by several chemical agents [28]. S. cerevisiae has also
been used as a model organism for evaluating other mitochondrial metabolism, including
the decrease production of reactive oxygen species when treated with DNP or energy
restriction [26]. Because of these organelle similarities, S. cerevisiae has been used since
the late 1960’s for making inferences about potential effects in other eukaryotic cells,
15

such as mammalian tissue [28]. Lastly, S.cerevisiae is ideal to use in cellular experiments
because of its single cell simplicity making it easier for the researcher to control
variables.
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Chapter 3 Methods and Materials
Laboratory Materials
1.5 ml Eppendorf (Sigma Genesis Catalog # Z376787 tubes St. Louis, MO)
1- 500 ml beaker (n = 1)
Glass luminosity tubes (Sigma Genesis Catalog # Z217638 St. Louis, MO)
Luminometer model # LUMAT9501 (Berthold Detection Systems, Black Forest,
Germany)
Hemocytometer (Reichert New York City, NY)
Saccharomyces cerevisiae (Wards catalog # 85w5010; Rochester, NY.)
Trypan Blue (Sigma Genesis catalog # T8154; St Louis, MO)
Adenosine 5'-triphosphate (ATP) Bioluminescent Assay Kit (Sigma Genesis
catalog # FLAA; St Louis, MO)
CelLyticä Yeast Cell Lysis/Extraction Reagent (Sigma Genesis catalog # C 4482;
St. Louis, MO)
2,4-Dinitrophenol (Sigma Genesis Catalog # 198501; St. Louis, MO)
HOTROXTM (Biotest Laboratories Lot #10007177, Exp. 1/2012; Colorado
Springs, CO.)
Centrifuge (capable of 7000 and 12000 x g)
Nutrient Broth
99.9999 % Ethanol Anhydrous Sigma Genesis Catalog # 459836; St. Louis, MO)
Vortex
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Experimental Design
This experiment cross compared the effects of A7E and DNP at varying doses on
the growth and ATP production in S. cerevisiae with a control treated with ethanol alone.
The control samples received 75 µl ethanol anhydrous while the experimental groups
received the same volume of ethanol with specific quantities of one of either test drugs.
After each sample received its respective treatment, all samples were incubated for 6 hr
under identical conditions. Observations from both the A7E test group and the DNP
positive control group were analyzed in comparison to control group. The dose
relationship of both the A7E and the DNP was assessed to identify similarities.
Instrumentation
Cell counts were taken to ensure that any decreased ATP observed was not an artifact
of any cytolytic effect of the uncoupling agents. Cell counts were counted using
hemocytometry while simultaneously measuring cell death using trypan blue exclusion
staining. Counts were performed using three quartiles of the hemocytometer per sample
to ensure accuracy. Luminosity in relative luminosity units (RLU) was measured using
10 sec measurement intervals. Because the reagent in the ATP bio-luminescence kit was
designed specifically to measure ATP, luminosity is a direct function of ATP present.
Luminosity has been used in previous experiments to measure diminished ATP resulting
from DNP treatment [22]. The following two reactions summarize the overall reaction of
ATP in the presence of luciferin (ATP bio-luminescence kit, Sigma) to generate light:
1. ATP + Luciferin Adenyl-luciferin + PPi
2. Adenyl-luciferin + O2 Oxyluciferin + AMP + CO2+ light
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Statistical Methods
ANOVA was used to test for group mean difference in luminosity. Tukey’s
correction was used to protect for potential familywise error resulting from multiple
pairwise comparisons. χ2 analyses were used to measure differences in cell counts and
cell viability. Bonferroni’s correction was used to control for familywise error from the
multiple comparison procedures. Alpha was set at 0.05 for luminosity for ANOVA
analysis, luminosity pairwise comparisons, cell count and vibility χ2.

Experimental methods
Creating DNP Treatment Solution
DNP stock solution was created containing 0.1334 mg DNP blend / µl of ethanol.
From the DNP stock solutions 2 other solutions were made which contained 0.0333 mg
DNP blend / µl of ethanol and 0.0666 mg DNP blend / µl of ethanol. These solutions
contribute 2.5, 5, or 10 mg of DNP suspended in 75 µl of ethanol anhydrous.
Creating A7E Treatment Solution
A7E stock solution contained 1.0667 mg A7E blend / µl of ethanol. Further
solutions created from stock solution created treatments providing 0.222 mg A7E blend /
µl of ethanol and 0.444 mg A7E blend / µl of ethanol. These dilutions provide 16.6, 33.3,
or 80 mg of A7E blend for each aliquot.
Group Assignment
Group titles were assigned as follows: Control- treated with ethanol, DNPHigh10∙mg DNP treatment, DNPMod- 5∙mg DNP treatment, DNPLow- 2.5 mg DNP
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treatment, A7EHigh- 80 mg A7E treatment, A7EMod- 33.3 mg A7E treatment,
A7ELow- 16.6 mg A7E treatment.
Saccharomyces cerevisae Culture
S. cerevisiae was inoculated into an autoclaved 500 ml beaker in sterile nutrient
broth, capped and incubated at 37º C with stir bar. The yeast grew for 7 days (168 hr).

Drug Exposure and Incubation
Once drug treatment dilutions were created, the stock yield was distributed into the
first set of numbered 1.5 ml Eppendorf tubes (identified as tubes numbered 1 to 36). Each
Eppendorf tube received 1 ml of stock cell culture while shaking. After stock yield was
distributed into the Eppendorf tubes the tubes were divided into seven groups:
Control group receiving 75 µl ethanol anhydrous (n = 6)
Three DNP groups receiving 75 µl assigned drug dilutions in five replicates per
dilution (n = 15 total)
Three A7E groups receiving 75 µl distinguished dilutions in 5 replicates per
dilution (n = 15 total)
36 total subjects were tested. See Table 1.
Table 1. Group Compositions

Group
CNT
DNP 2.5
DNP 5
DNP10
A7E 20
A7E 40
A7E 80
n=

Number of
Subjects
6
5
5
5
5
5
5
36
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All tubes containing drug exposures were consistently vortexed for 6 sec at
approximately 1000 RPM just prior to treatment administrations. After the cultures were
treated they were incubated at 37º C while shaking for 6 hr.

Cell Lysis and ATP Recovery
The cells were lysed following 6 hr of uncoupling agent treated incubation
following protocol modified from CelLyticä bulletin. The tubes were centrifuged at
7000× g for five min in a refrigerated room. Because the centrifuge only held 18 tubes,
the subjects were centrifuged in two sets one immediately following the other. Cells
were pelleted and the supernatant discarded. The cells then received 1 ml of CelLyticä
yeast lysing agent. The tubes were placed on a vortex for 15 min at approximately 500
RPM to allow the tubes to shake. Immediately following vortexing, the tubes were
centrifuged at 12000 × g for ten min to pellet the cellular debris. After centrifugation, 1
ml of the ATP containing supernatant was pippetted and placed in a new, sterile and
cooled 1.5 ml Eppendorf tube that was numbered to its corresponding supernatant donor.
The samples were kept on ice and transported to Cancer Research Facility (CRF)
laboratory, located at North Campus of the University of New Mexico. This transport
took approximately 15 min total.

Measuring Luminosity
Per manufacturer’s protocol, 0.1 ml ATP assay solution was added to an empty
reaction vial and allowed to stand at room temperature for 3 min. After one min assay
acclimation had passed, a second 0.1 ml ATP assay solution was added to an empty
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reaction vial and allowed to stand at room temperature for 3 min. This was repeated for
each sample to reduce the amount of time necessary for each measurement. Upon
completion of the three min assay acclimation, 0.1 ml of the first sample was mixed with
the ATP assay reagent, placed in a vortex for approximately six sec and immediately
placed into the luminometer for measurement of intensity. The measurements were
recorded. This procedure was repeated for each sample. This process took approximately
one hour preparing one reagent every minute for measurement (thus, more than one
sample was reacting, while the previous sample was being measured) and immediately
measuring and recording, then repeating. Supernatants were measured in the order that
their respective cells were lysed.

Cell Density
Hemocytometery was used to calculate cell density. S. cerevisiae cells were
incubated at 37º C for 168 hr while shaking. At baseline (initial introduction of S.
cerevisiae to treatment) cell density of common yield was measured. After initial
measurement, ethanol anhydrous treatment (control) was administered to six control
subjects and incubated. The first DNP and A7E dilutions were created using the same
protocol as previously described (see “Creating DNP Treatment” and “Creating A7E
Treatment”). The first DNP and A7E treatment groups received their assigned treatment
30 min after initial control incubation. These steps were repeated for the second and third
treatment of each drug with 30 min displacement between each of the four treatment
windows. The 30 min treatment window allowed for accurate cell counts to be taken 6 hr
after each culture was incubated. Because six hr presented enough time for significant
cell division to occur, I created a no treatment (NT) group. This NT group was incubated
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six hr prior to each group control. This allowed us to analyze any differences in cell
counts due to culture maturation. After six hr from baseline, the control subjects were
measured. Samples of 20 µl from three of the control vials were combined with 60 µl of
trypan blue in a small plastic tube. The solution was gently mixed and left to stand at
room temperature for 5 min. Samplings of 10 µl of the preparations were counted for
stained cells and total cells using a hemocytometer. The procedures were repeated three
additional times for each wave of 6 hr incubated cells. All counts were recorded in an
Excel spread sheet.

Data Collection and Analysis
Luminosity
Analysis of variance was used to determine if there was a significant difference
between group luminosities. ANOVA F statistic was generated using equation 1.
Equation 1. F= Variation among sample means/variation among individuals

Uncoupling agents affect luminosity such that the more effective the uncoupler, the less
luminosity present. All groups generated consistent measurements within respective
groups. In order to control for the difference in variance between groups the natural log
(ln) of each individual measurement was taken and used for the analysis of variance.
Pair-wise comparisons were used to assess difference between groups. Tukey’s
correction factor was used to control for familywise error. Alpha was set to 0.05 for
luminosity ANOVA and luminosity pairwise comparisons.
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Cell Density
Difference in cell density between groups was analyzed using χ2tests. The χ2
analysis measures how far the observed values of two-way table are from the predicted
values. The χ2 statistic was generated using equation 2.
Equation 2. χ2=∑ (observed count – expected count)2 / expected count
.
χ2 was performed three times for distinct comparisons between hypothesized relative
strengths of DNP, A7E with a control. Alpha was set at 0.05.
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Chapter 4 Results
Luminosity / ATP
Mean luminosity for groups DNPLow, DNPMod, and DNPHigh were lower than
the average luminosity of the control group (Figure 8). Mean luminosity for groups
A7ELow, A7EMod, and A7EHigh were all numerically lower than the control group
average luminosity. Every treated individual sample generated less luminosity than every
control treated individual sample. Figure 9 illustrates transformed luminosity values with
log mean, low, first quartile, third quartile and high values for each group.

Luminosity
RLU

40000

31645

24596

30000
20000

Control

16038

17191

DNP

11901

6969

A7E

10000
767
0
Control

A7E
DNP
Control

Low

Mod
Treatment Level

High

Figure 8. Group Mean Luminosity
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Figure 9. Group Log Luminosities

ANOVA and Pairwise Comparison Results
The ANOVA test revealed that F (6, 29) = 149.37 and p < 0.0001. Table 2 summarizes
individual adjusted p values for each group pairwise comparisons.
Table 2. Group Luminosity Pairwise Comparisons

Groups Compared

p-adjusted

DNPLow-control
DNPMod-control

0.0014
0.0000

DNPHigh-control
A7ELow-control

0.0000
0.5620

A7EMod-control
A7EHigh-control

0.0006
0.0000

A7ELow-DNPLow
A7EMod-DNPMod

0.1410
0.1340

A7EHigh-DNPHigh

0.0000
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Cell Counts
Cell counts showed that all groups generated average total cell counts less than 50
across the sample sets. Group A7EHigh generated nearly three times the total cell density
of any other observed value. All groups generated cell deaths less than 15 cells. Figure 10
illustrates the group means of cell density and cell death and Table 3 is the observed
values of both cell density and cell death. See Discussion for description of outlier. Group
mean cell counts both total and dead are summarized in Table 4 along with the results

Number of cells observed

from the χ2 analyses.

50
40
30
20
10
0

Dead
Dead

Total

Treatment groups and comparison group clusters

Figure 10. Group Mean Cell Counts and Deaths. No Treatment (NT) Tubes were used to compare
changes in cell density and/or viability as a result of time progression.
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Quartile 1*
Dead Total
0
25
5
26
5
21
2
12

Group
NT
NT
NT
NT

Time
805am
836am
924am
950am

NT
Control
DNPHigh
A7EHigh

200pm
219pm
233pm
248pm

5
2
1
5

Control 257pm
DNPMod 316pm
A7EMod 335pm
Control
DNPLow
A7ELow

351pm
422pm
444pm

Table 3. Individual Group Cell Counts
Quartile 2*
Quartile 3*

Total
Dead Total
1
58
14
86
7
44
5
36

Mean
Dead
Total
0.333
19.3333
4.666
28.666
2.333
14.666
1.666
12

Dead
1
4
1
1

Total
17
39
13
10

Dead
0
5
1
2

Total
16
21
10
14

14
17
7
54

3
3
3
4

23
12
9
39

2
3
3
4

15
13
11
51

10
8
7
13

52
42
27
144†

3.333
2.333
2.333
4.333

17.333
14
9
48

3
6
1

18
28
14

1
3
3

19
23
14

2
1
1

15
23
17

3
10
5

52
74
45

1
3.333
1.666

17.333
24.666
15

2
1
4

6
15
16

1
3
4

7
18
20

1
4
2

4
18
22

5
8
10

17
51
58

1.666
2.666
3.333

5.666
17
19.333

*Quartile number refers to the area of the hemocytometer.
†Outlier (described in Discussion)
Table 4. Group Mean Cell Counts with Respective χ2 Analyses p Values

Analysis 1 (High)
Group
Dead
Alive
CNT
8
34
DNPHigh
7
20
A7EHigh
13
131
p = 0.04541

Analysis 2 (Moderate)
Group
Dead
Alive
CNT
3
49
DNPMod
10
64
A7EMod
5
40
p = 0.374
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Analysis 3 (Low)
Group
Dead
CNT
5
DNPLow
8
A7ELow
10
p = 0.4309

Alive
12
43
48

Chapter 5 Discussion
Luminosity / ATP
There was a dose-dependent lowering of luminosity by both DNP and A7E
treatments compared with control. The measurement for tube 5 was abnormally high in
luminosity and was therefore repeated two more times. The mean was used as true value
for tube 5. The ANOVA test revealed that F (6, 29) = 149.37 and p = 2.2 × 10-16 leading
to the conclusion that all groups compared to one another were not the same, thus
rejecting the null. For pairwise comparisons and respective p-values see Table 2. All
groups were significantly different (p < 0.05) from the control group with the exception
of group A7ELow. All other groups reject their relative null hypotheses with the finding
that there is significant difference in luminosity between group DNPLow and control,
group DNPMod and control, group DNPHigh and control, group A7EMod and control,
and group A7EHigh and control. A summary of all results is illustrated in Figure 9. Table
2 summarizes p-values adjusted for familywise error for group comparisons to control.
These results are supportive evidence that A7E does act as an uncoupling agent, as does
DNP, as predicted in my hypothesis.
A7E Compared to DNP
In order to assess the presence of common dose dependent relationship, A7E was
compared to DNP using pair-wise comparisons. The groups were paired by order of
dilution; DNPLow and A7ELow, DNPMod and A7EMod, and lastly DNPHigh and
A7EHigh. There was not a significant difference between the low drug treatment groups,
DNPLow and A7ELow, which fails to reject null. Also the medium drug treatments
failed to reject the null indicating no difference between the two. There was, however, a
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significant difference in luminosity production between groups DNPHigh and A7EHigh,
thus, resulting in the rejection of the null. The significance of these findings illustrates
that there appear to be uncoupling agents that are less effective by weight than DNP, but
still remain effective enough performing proton translocation to have a pronounced affect
on metabolism. Moreover, A7E showed increased uncoupling potential with an increase
in dose illustrating a dose dependence on effectiveness, suggesting A7E may provide an
uncoupling agent with effectiveness and a wider range of therapeutic doses, likely a
beneficial characteristic.
Cell Density
χ2 analysis found no differences between NT groups and control groups showing
there was no significant cell growth during the time that passed during cell counts. The
first χ2analyses compared the strongest drug concentrations plus a control (DNPHigh,
A7EHigh and Control). The second analysis included the second dilutions (DNPMod,
A7E Mod and Control) and the last analysis compared the weakest concentrations (third
dilutions which included DNPLow, A7ELow and Control). The first analysis comparing
the high dose showed that the groups generated significantly different cell densities (p =
0.04541) which could be a result of cell “clumping”. Based on luminosity values for
group A7Ehigh it is unlikely that the cell density was actually twice that of any other
group including controls which suggests presence of an outlier. Moreover, when
individual χ2 were performed comparing each pairing of A7EHigh, DNPHigh, and the
control with use of Bonferroni’s adjustment to control for familywise error, there was no
significant difference between the groups in cell viability or cell density. The second
comparison between moderate doses concluded the groups were not significantly
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different from one another (p = 0.374) demonstrating cell densities were not statistically
different. The last analysis compared the weakest drug dilutions (DNPLow and A7ELow)
and showed no significant difference in cell densities between groups (p = 0.4309). The
data fails to reject the null hypotheses, that there is a difference in cell density or viability
between group pairings. See Table 4 for cell densities with independent group
comparisons and p-values. This data supports the conclusion that treatment with DNP
and A7E in the tested quantities did not kill cells or diminish growth (in comparison to
control), permitting the assumption that any changes in ATP production (as evidenced by
reduced luminosity measurements) were likely due to uncoupling.
Luminosity and Cell Density
The most significant finding was the similar relationship between A7E and DNP
in the reduction of luminosity. This follows the prediction that, as uncoupling agent
concentration increases in mitochondria, less ATP is produced, thus reducing luminosity.
Further, neither agent generated significantly lower cell densities in comparison to the
control which suggests that the DNP did uncouple mitochondrial metabolism as
documented by previous studies. A7E appeared to function identically to DNP, only in a
less efficient fashion. Only the low dose administration of A7E failed to generate
significantly less luminosity than the control suggesting 16.6 mg of A7E was not
sufficient uncoupling agent to significantly lower ATP production in comparison to the
control group. It is, however, important to note that both the mean and all observed
values of group A7ELow were numerically lower than both the mean and all values of
the control. Also similar to DNP, the A7E did not generate significantly different cell
density or viability from control. Because of the greater quantity of agent, these findings
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suggest A7E performs mitochondrial uncoupling less efficiently that DNP. Moreover,
pair-wise comparisons of drug dilutions against one another between both treatments
revealed no statistical difference between DNPLow and A7ELow. The same is true of
groups DNPMod and A7EMod. Groups A7EHigh and DNPHigh were statistically
different most likely because that DNP may be more than eight times more effective than
A7E based on 8 × more A7E than DNP by weight. Mean luminosity suggests it is
reasonable to hypothesize that DNP is approximately 16 times more effective at
mitochondrial uncoupling. Furthermore, with the dilution variance set at eight fold, as
DNP approached total uncoupling (no ATP produced), the magnitude of uncoupling
significantly surpassed that of A7E. Had the doses been tested at similar weight of DNP
but approximately twice as much A7E the luminosity trend slopes of the two agents
might have been nearly parallel elucidating a dose related trend. The collective
luminosity and cell density data illustrates that A7E and DNP function as uncoupling
agents, and that A7E is less efficient than DNP as predicted in my hypothesis.

Conclusion
A7E performs the function of mitochondrial uncoupling and does so less
effectively than DNP. It is possible that A7E is an uncoupling agent with a wider range of
therapeutic dose, thus, potentially reducing its toxicity and heightening the variety of
doses that might benefit people seeking to use uncoupling agents to increase metabolic
rate for weight loss. A7E may present a potential option for individuals attempting a
weight loss regimen. A7E could augment mitochondrial uncoupling resulting in an
increased energy deficit assisting in weight loss.
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Limitations to this Study
1. It is difficult to determine if the observations of lower ATP generated from the
A7E group resulted solely from mitochondrial interference and not partially due
to the reduced ability of the S. cerevisiae to absorb nutrients. Cell culture and
viability counts were measured to assess replication and death, and it appears that
uncoupling is likely the main interference diminishing ATP production.
2. It is also difficult to distinguish if another mechanism resulting in the reduction of
ATP production could be occurring (such as that observed in hydrogen cyanide
inhibition of Cytochrome C Oxidase).
3. It is difficult to determine which component of the proprietary blend found in
HOTROXTM is responsible for the decreased presence of ATP. One of the agents
in A7E could be working to degrade or preserve ATP. A7E purportedly contains
caffeine which acts as a phosphodiesterase inhibitor which could add to the
stability of ATP, which could increase luminosity thereby reducing the observed
uncoupling effect.
4. There is also a possibility that the assay could misidentify the nucleotide (e.g
mistake ATP for GTP).
5. This work has not deciphered if A7E is actually less effective than DNP at
uncoupling, or if there is some other variable that is limiting the rate at which the
A7E can uncouple or is modulating the accumulation of ATP.
6. This work was performed in the eukaryote S. cerevisiae. While this
microorganism has mitochondria similar to human mitochondria, many variables
could change how A7E works in human; for example, absorption in the gut. The
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human gastrointestinal tract is much more complex than the cell wall of a
eukaryote and could result in further decreased drug efficacy. A7E is readily
available over-the-counter and should be tested further in humans.
7. As noted from the observed results it appears that A7E is approximately 16 times
weaker at proton translocation than DNP so further work should be done to
describe the ratio of efficacy between the two.
8. This work should be repeated in animal models to identify if the effects on ATP
observed at the cellular level are transferable to mammals. Mammal experiments
could also be used to elucidate other possible effects on metabolism, as well as
side effects that are not predicted.

Future Research
Uncoupling proteins and uncoupling agents have a profound history influencing
metabolism. The next area that needs to be researched is the effects that uncoupling
agents have on the genome. Varied durations of exposure and varied amounts of
uncoupling agents may manipulate an organism’s genome to have a higher metabolic
rate, possess more oxidative mitochondria per cell, and a number of other combinations
that may influence humanity well beyond the scope of human obesity. The next series of
tests that should be run is the influence that uncoupling agents have on mitochondrial
biosynthesis. These tests should be explored first in cell cultures, then in mammals to
assess change in weight and mitochondrial density.
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Appendix

A7EHigh

A7EMod

A7ELow

DNPHigh

DNPMod

DNPLow

Control

Individual tube luminosity measurements

Tube #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Luminosity Measurement #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
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Luminosity
(RLU)
30601
30806
31439
29867
34722
32439
20425
19906
18656
9512
17458
24375
9861
9344
7971
7955
874
730
944
657
633
24520
23735
24295
23411
27022
14433
15102
19342
16215
15102
7520
7699
6800
7359
5470

